Black Diamond Therapeutics, Inc. (BDTX)
1.36
-0.03
(-2.16%)
USD |
NASDAQ |
Nov 20, 09:39
Black Diamond Therapeutics Cash from Operations (Quarterly) : -8.338M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -8.338M |
| June 30, 2026 | -7.968M |
| March 31, 2026 | -10.23M |
| December 31, 2025 | -6.787M |
| September 30, 2025 | -7.85M |
| June 30, 2025 | -9.159M |
| March 31, 2025 | 53.41M |
| December 31, 2024 | -15.06M |
| September 30, 2024 | -11.32M |
| June 30, 2024 | -14.73M |
| March 31, 2024 | -21.20M |
| December 31, 2023 | -13.96M |
| September 30, 2023 | -18.36M |
| June 30, 2023 | -14.37M |
| March 31, 2023 | -20.03M |
| December 31, 2022 | -21.94M |
| Date | Value |
|---|---|
| September 30, 2022 | -16.48M |
| June 30, 2022 | -18.07M |
| March 31, 2022 | -28.60M |
| December 31, 2021 | -24.05M |
| September 30, 2021 | -26.48M |
| June 30, 2021 | -25.16M |
| March 31, 2021 | -24.46M |
| December 31, 2020 | -15.77M |
| September 30, 2020 | -11.49M |
| June 30, 2020 | -13.57M |
| March 31, 2020 | -11.32M |
| December 31, 2019 | -7.511M |
| September 30, 2019 | -5.285M |
| June 30, 2019 | -5.00M |
| March 31, 2019 | -6.878M |
| December 31, 2018 | -2.384M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Lineage Cell Therapeutics, Inc. | -5.62M |
| Armata Pharmaceuticals, Inc. | -5.516M |
| Voyager Therapeutics, Inc. | -19.67M |
| Invivyd, Inc. | -32.11M |
| Elicio Therapeutics, Inc. | -10.36M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 4.218M |
| Cash from Financing (Quarterly) | 0.012M |
| Free Cash Flow | -33.32M |
| Free Cash Flow Per Share (Quarterly) | -0.1451 |
| Free Cash Flow to Equity (Quarterly) | -7.404M |
| Free Cash Flow to Firm (Quarterly) | -8.338M |
| Free Cash Flow Yield | -42.64% |